Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim revealed their intensions to conduct two outcome studies investigating the diabetes drug, Jardiance, for the chronic heart failure treatment. According to the company, the trials were targeted to commence within the one year and planned to enroll people with a similar kind of ailment with, as well as without type two diabetes (T2D).

Eli Lilly said JARDIANCE was the first diabetes treatment to exhibit a reduction in the risk of cardiovascular (CV) death in a dedicated CV outcomes trial. The pharmaceutical firm added that this was showcased on top of standard of care, which included glucose-lowering agents and CV drugs, in people with T2D at high risk of CV events.

Aside from reducing CV death by 38 percent, the EMPA-REG OUTCOME trial also demonstrated that JARDIANCE reduced the risk of hospitalization for heart failure with T2D at high risk of CV events. The companies disclosed that such results forced them to the planned trials.

See more from Benzinga

• Flextronics Hires John Carlson As President For Flex Medical Solutions

• LSB Industries To Release Q1 Results On May 4

• EMC And Presidio To Store Data For NBC Olympics In Data Lake For Real-Time Digital Broadcast

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.